Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

16 results about "Retina cell" patented technology

Multiband LED epitaxial structure and preparation method thereof

ActiveCN120897586AMaterials scienceRetina cell
The invention discloses a multiband LED epitaxial structure and a preparation method thereof, and relates to the technical field of semiconductors. A multi-quantum well light-emitting layer of the multiband LED epitaxial structure comprises a first long-wave blue light multi-quantum well light-emitting layer, a second medium-wave blue light multi-quantum well light-emitting layer, a third short-wave blue light multi-quantum well light-emitting layer and a fourth short-wave blue light end quantum well light-emitting layer which are sequentially stacked. The LED chip manufactured through the epitaxial structure can emit light of three different wave bands including long-wave blue light, medium-wave blue light and short-wave blue light, the excitation light source with the blue light of the three wave bands excites the red-green mixed fluorescent powder layer, a full-spectrum white light LED light source can be generated, and compared with a blue light LED chip with only one wave band, the full-spectrum white light LED light source has the advantages that the light emitting efficiency is improved, and the light emitting efficiency is improved. The ratio of short-wave blue light below 450 nm is small, damage to human eye retina cells is small, and a healthy full-spectrum white light LED light source with a high color rendering index can be achieved.
Owner:JIANGXI ZHAO CHI SEMICON CO LTD

Spherical lens and cylindrical lens double-control fusion lens

The utility model relates to the technical field of lenses, in particular to a spherical lens and cylindrical lens double-control fusion lens, which comprises a lens body and is characterized in that the lens body comprises a base layer I, and an anti-reflection layer, an ultraviolet-proof layer, an impact-resistant layer, a photochromic layer and a stain-resistant layer are arranged on the surface of the lens body. An anti-reflection layer is fixedly adhered to one side of the base layer I through a resin adhesive, and an ultraviolet-proof layer is adhered to the other side of the anti-reflection layer through the resin adhesive. According to the scheme, the functionality is remarkably improved through the multi-layer composite structure design (the anti-reflection layer, the ultraviolet-proof layer, the anti-impact layer and the like), in addition, the micro lenses of the first base layer and the second base layer are distributed in a staggered mode by rotating by 30 degrees, the one-person two-mirror alternate wearing mechanism (alternating every 2-4 weeks) is combined, fatigue of retina cells caused by fixed stimulation is avoided through dynamic out-of-focus stimulation, and the anti-fatigue performance of the retina cells is improved. Meanwhile, alternate recovery is promoted, so that myopia development is intervened more scientifically.
Owner:JIANGSU SHENGPU OPTICAL TECH CO LTD

Construction method of a prpf6 gene mutation-induced haploinsufficiency rp mouse model and application thereof

ActiveCN119769472BHydrolasesMicroinjection basedDisease phenotypeHaploinsufficiency
The application discloses a method for constructing a RP mouse model caused by Prpf6 gene mutation and haploinsufficiency and application thereof, and belongs to the field of molecular biology and biomedical technology. The mouse model constructed by the method provides a convenient, reliable and economical means for studying the relationship between the PRPF6 gene mutation and the retinal pigment degeneration disease and the pathogenic mechanism thereof, and provides a stable hereditary effective research model in the research of the pathogenic mechanism, treatment method and drug screening of RP. The animal model is subjected to transcriptome and a series of type detection, wherein the transcriptome result shows that the retina of the Prpf6 gene knockout mouse has a certain degree of metabolic abnormality, and the results of the electro-physiological detection, fundus examination and H&E staining show that the cell layer of the mouse retina and the shape and function of the retina are damaged, which is consistent with the disease phenotype of RP.
Owner:JIANGNAN UNIV

RNA, pharmaceutical compositions, conjugates and applications

ActiveCN119899836BOrganic active ingredientsSenses disorderNucleotideGlial activation
The present application relates to the technical field of retinal ischemia-reperfusion injury, and specifically to RNA, pharmaceutical compositions, conjugates and applications. The nucleotide sequence of the RNA is shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. The RNA can inhibit the proliferation of retinal Müller cells, increase the changes in mitochondrial membrane potential of retinal Müller cells, promote Müller cell apoptosis, reduce Müller cell glial activation and protect ganglion cells from damage, reduce the inflammatory response of retinal ischemia-reperfusion injury, and has application prospects in the prevention and treatment of retinal ischemia-reperfusion injury.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL +1

Adeno-associated virus variant and use thereof

Disclosed are adeno-associated virus (AAV) capsid protein variants that have improved infectivity and transduction efficiency for target cells, and uses thereof. Specifically, the disclosure relates to AAV2 variant capsid proteins selected by directed evolution for gene delivery to retinal cells, recombinant AAV vectors comprising the same, and uses thereof as gene delivery vehicles to retinal cells.
Owner:UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY

Eye washing liquid for relieving eye fatigue and preparation method thereof

The invention relates to the technical field of nursing materials, and discloses eye washing liquid for relieving eye fatigue and a preparation method thereof.The eye washing liquid is prepared from trehalose, taurine, sodium gualenate, sodium hyaluronate, ergothioneine, vitamin B12, vitamin B6, xanthophyll, mint, a humectant, a bacteriostatic agent, a chelating agent, a pH regulator and deionized water. Through the synergistic effect of the first synergistic composition and the second synergistic composition, retina cell injury induced by blue light can be effectively repaired, the repairing effect is superior to that of simple addition of a single component, blue light oxidative injury is repaired through a multi-target synergistic mechanism, a three-layer structure of a tear film lipid layer, a water layer and a mucoprotein layer can be reconstructed, and the repairing effect is good. According to the present invention, the tearable film stability is significantly improved, the excellent protection and repair effect is provided, the compatibility of the components is good, the product stability is high, and the multiple effects of ocular surface cleaning, asthenopia relieving, conjunctival congestion reducing and blue light oxidation damage preventing are provided.
Owner:TIANYAN MEIHA(JIANGSU)BIOTECHNOLOGY CO LTD

A gene therapy method targeting USP8 for the treatment of retinal degenerative diseases and its application

This invention discloses a gene therapy method targeting USP8 for the treatment of retinal degenerative diseases and its application. The study found that USP8 expression is downregulated in aging and retinal degenerative disease mouse models; knockout... Usp8 Mice exhibiting retinal degeneration showed signs of retinal degeneration, and overexpression of USP8 was able to rescue these lesions. This finding indicates that USP8 plays a crucial role in maintaining retinal cell homeostasis and delaying retinal degeneration. Regulating USP8 expression levels can significantly improve retinal function, providing a novel potential target and strategy for the treatment of retinal degenerative diseases.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Lipid nanoparticle compositions and uses thereof

The present disclosure relates to pharmaceutical compositions comprising a lipid nanoparticle (LNP), a therapeutic nucleic acid (TNA) and at least one pharmaceutically acceptable excipient, wherein the LNP comprises at least one lipid, and wherein the LNP is capable of delivering the TNA to a retinal cell. Methods of treating ocular diseases and disorders are also provided.
Owner:GENERATION BIO CO

Negative oxygen ion eye protection lamp capable of inhibiting myopia and relieving asthenopia

The invention relates to the technical field of lighting equipment, in particular to a negative oxygen ion eye-protection lamp capable of inhibiting myopia and relieving asthenopia, which comprises an eye-protection lamp body, a lamp post and a negative oxygen ion generator, the eye-protection lamp body is used for emitting full-spectrum light; the negative oxygen ion generator is installed at the joint of the eye protection lamp body and the lamp pole, and the concentration of negative oxygen ions generated by the negative oxygen ion generator is 5000-5000 / cm < 3 >. When the eye protection lamp is used, the negative oxygen ion generator is arranged at the joint of the eye protection lamp body and the lamp pole, the negative oxygen ion generator can generate negative oxygen ions with the concentration of 5000-50000 / cm < 3 >, more dopamine is secreted by a living body through the negative oxygen ions, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and therefore the eye protection effect is improved. Therefore, the visual comfort is improved, and the effects of inhibiting myopia and relieving asthenopia are achieved.
Owner:ANHUI BOLIN HEALTH TECHNOLOGY CO LTD

Use of mir-15a-5p in treatment of fundus oculi disease

The present disclosure relates to the technical field of biomedicine, and in particular to use of miRNA or modified miRNA in treating fundus oculi diseases. The miRNA or modified miRNA has biological activity, can be absorbed by cells in vitro or retina cells in vivo, and quickly plays a biological role. Through a topical administration mode, the miRNA or the modified miRNA can inhibit pathological neovascularization, promote recovery of a non-perfusion region, reduce expression of retinal inflammatory factors, relieve retinal fibrosis, and promote nerve injury repair. The method has very good application and research values in the field of biomedicine.
Owner:TIANJIN MEDICAL UNIVERSITY EYE HOSPITAL

Multi-band LED epitaxial structure and preparation method thereof

ActiveCN120897586BMaterials scienceRetina cell
The application discloses a multi-waveband LED epitaxial structure and a preparation method thereof, and relates to the technical field of semiconductors. The multi-waveband LED epitaxial structure is characterized in that the multi-quantum well light-emitting layer comprises a first long-wave blue light multi-quantum well light-emitting layer, a second middle-wave blue light multi-quantum well light-emitting layer, a third short-wave blue light multi-quantum well light-emitting layer and a fourth short-wave blue light multi-quantum well light-emitting layer which are stacked in sequence. The LED chip prepared by using the epitaxial structure can emit three different wavebands of long-wave blue light, middle-wave blue light and short-wave blue light. The excitation light source with the three wavebands of blue light can excite a red-green mixed fluorescent powder layer to generate a full-spectrum white light LED light source. Compared with the blue light LED chip with only one waveband, the short-wave blue light with a wavelength of less than 450 nm accounts for a small proportion, the damage to the human eye retina cells is small, and the healthy full-spectrum white light LED light source with a high color rendering index can be realized.
Owner:JIANGXI ZHAO CHI SEMICON CO LTD

Gene therapy method for treating retinal degenerative diseases by targeting USP8 and application of gene therapy method

The invention discloses a gene therapy method for treating retina degenerative diseases by targeting USP8 and application of the gene therapy method. The research finds that the USP8 expression in an aging and retinal degeneration mouse model is down-regulated; the mouse with Usp8 knockout has retinal degeneration, and the retinal degeneration can be rescued through USP8 overexpression. The discovery shows that the USP8 plays a key role in maintaining the steady state of retinal cells and delaying the retinal degeneration process. By regulating and controlling the expression level of the USP8, the retina function can be remarkably improved, and a new potential target and strategy are provided for treatment of retinal degenerative diseases.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Methods for the production of retinal cells

The general inventive concepts contemplate methods and compositions for modifying certain cell lines to facilitate the production of retinal tissue from human induced pluripotent stem cells. Human induced pluripotent stem cells can be cultured to develop into retinal organoids, among other cells types. The retinal organoids play a role in modeling both human retinal development and retinal disease. The methods and compositions discussed herein provide means to measure and monitor human induced pluripotent stem cells during development.
Owner:UNIV OF MIAMI

Eye protection lamp capable of inhibiting myopia and relieving fatigue

The invention relates to the technical field of lighting equipment, in particular to an eye protection lamp capable of inhibiting myopia and relieving fatigue, which comprises a shell and a negative ion generator, a substrate, a light source module and a light guide plate are sequentially arranged in an inner cavity of the shell from inside to outside, and the light source module is provided with a blue light bead group, a purple light bead group and a dark red light bead group. The wavelength of a light source emitted by the light source module ranges from 385 nm to 780 nm, the wavelength of a light source emitted by the purple light lamp bead set ranges from 385 nm to 420 nm, and the wavelength of a light source emitted by the dark red light lamp bead set ranges from 650 nm to 780 nm. During use, the ultraviolet lamp bead group with the light source wavelength of 385-420 nm and the dark red lamp bead group with the light source wavelength of 650-780 nm are arranged in the light source module and are matched with the negative ion generator for use, so that organisms are promoted to secrete more dopamine, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and the growth of the ocular axis is inhibited; the vision comfort is improved, myopia is inhibited, the blood oxygen concentration is increased, free radicals in the body are eliminated, and fatigue is relieved.
Owner:ANHUI BOLIN HEALTH TECHNOLOGY CO LTD